<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150810</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-103</org_study_id>
    <secondary_id>2017-001553-14</secondary_id>
    <nct_id>NCT03150810</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myriad Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, efficacy and clinical activity of BGB-290 and
      temozolomide (TMZ) in participants with locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study of BGB‑290 and temozolomide (TMZ) with a dose escalation and dose
      expansion phase. Dose escalation will evaluate safety, tolerability, preliminary efficacy,
      and PK and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) for
      the two drug combination. It is a modified 3+3 dose escalation scheme with a fixed dose of
      BGB‑290 in combination with escalating doses of TMZ. Dose expansion will evaluate the safety,
      PK profile and anti-tumor activity of BGB-290 and TMZ at a dose/schedule selected from the
      dose escalation phase. Five different solid malignancy types (n=100) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.</measure>
    <time_frame>From first dose BGB-290 to 28 days post-dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE.</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dosing.]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters (Cmax) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters (Tmax) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as assessed using RECIST.</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression while participant is alive, assessed to up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression or death, whichever is first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose BGB-290 until date of death, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects to receive continuous BGB-290 and TMZ (Days 1 - 7 of 28 day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects to receive continuous BGB-290 and continuous TMZ (28-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 100 subjects to receive BGB-290 and TMZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>BGB-290</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>TMZ</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>Dose/schedule selected based on dose escalation phase.</description>
    <arm_group_label>Arm C (Dose Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Dose/schedule selected based on dose escalation phase.</description>
    <arm_group_label>Arm C (Dose Expansion)</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥18 years old with advanced or metastatic stage solid tumors

          2. Eastern Cooperative Oncology Group (ECOG) status ≤ 1 and measurable disease per RECIST
             V1.1 (except for patients in dose escalation and prostate cancer patients)

          3. Additional inclusion criteria for dose expansion cohorts:

        Patients with homologous recombination deficiency (HRD+) or known BRCA mutant Ovarian
        cancer

        a. Previously received at least 1 line of platinum containing chemotherapy and No
        progression or recurrent disease in 6 months from last platinum containing regimen.
        Patients with HRD+ or known breast cancer susceptibility gene (BRCA) mutant Triple-Negative
        Breast Cancer

        a. 0 - 1 prior platinum-containing regimen (any treatment setting) and received ≤ 3 prior
        regimens (advanced or metastatic setting).

        Patients with HRD+ or known BRCA mutant Prostate cancer

          1. Chemotherapy-naïve or previously received ≤2 taxane-based regimens.

          2. May have pre-or post-treatment with a novel androgen receptor targeted agent. Small
             cell lung and gastric cancer

        a. Previously received ≤ 2 prior lines of therapy.

        Key Exclusion Criteria: All patients

          1. Prior exposure to a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.

          2. Refractory to platinum-based therapy.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Andreu Vieyra, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1 (877) 828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas- MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catalia d'oncologia- l'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START-Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Prostate cancer,</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>neoplasms</keyword>
  <keyword>temozolomide</keyword>
  <keyword>BGB-290</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>alkylating, alkylating agents,</keyword>
  <keyword>Poly (ADP-ribose) polymerase inhibitors</keyword>
  <keyword>enzyme inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

